Transforming Cancer Care

Charged Particles 4 Cancer Therapy (CP4CT)
Innovative research paving the way for cutting-edge cancer treatments

Our Mission

CP4CT is driven by a conviction that pioneering cancer research that integrates physics, engineering, and medical expertise will drive meaningful breakthroughs in treatment. 

Our goal is to establish a world-class scientific facility as the foundation of these efforts.  Foster multi-disciplinary collaboration and innovation, pushing the boundaries of what is possible in cancer care, and accelerate the development of life-saving treatments and technologies.

Why we do it?

Cancer remains one of the most challenging health crises of our time, affecting millions of lives globally. 

Despite significant advancements, patients with cancer still have limited access to advance curative cancer treatments such as ion-beam radiotherapy (PBT).

By using protons or ions such as carbon instead of X-rays to deliver radiotherapy, PBT is able to deliver dose more precisely to the tumor and reduce side effects.

Our initiatives will focus on overcoming barriers with cutting-edge technology that will make high-precision radiotherapy tailored to the particular patient and tumor more accessible, cost-effective, and successful.

Our Solution:
The LhARA Initiative

Through the LhARA initiative we aim to transform proton and ion-beam therapy by developing a ground-breaking new laser-based cancer treatment. 

To do this we will deliver a targeted multidisciplinary R&D program focused on: 

  • Reducing the footprint and investment cost of proton- and ion-beam therapy facilities

  • Increasing treatment capacity to cope with large volumes of patients in shorter amounts of time

  • Enhancing treatment effectiveness through real-time automated personalization for each individual patient

  • Advancing fundamental biological research to optimize radiation therapy

  • Developing new systems and processes that improve overall treatment efficiency

Together with our supporters, we are reshaping the future of cancer care. 

Phase 1

Strategic, targeted research and development

Phase 2

Construction of pre-clinical research facility

Phase 3

Clinical development

Collaborate

We seek to engage and inspire a diverse network of stakeholders, including: 

  • Philanthropic Organisations & Foundations: Key funders who align with our mission and vision for cancer innovation. 

  • Medical & Scientific Communities: Experts in oncology, physics, and engineering who can contribute to and benefit from our research. 

  • Investors & Donors: Individuals and organisations passionate about supporting cutting-edge cancer research and clinical advancements. 

Trustees

  • Professor Iain McNeish

    Professor Iain McNeish is Head of Cancer at Imperial College London and Director of the Ovarian Cancer Action Research Centre. He co-leads Imperial’s NIHR BRC Cancer Theme and the Experimental Cancer Medicine Centre. His research focuses on ovarian cancer biology and developing new therapies using advanced models and biomarkers.

  • Professor Amato J. Giaccia

    Professor Amato Giaccia is a leading cancer researcher at Stanford University, known for his work on how the tumour environment affects treatment resistance. He has received major awards, including the ASTRO Gold Medal and an NIH Outstanding Investigator Award. He also co-authored a widely used textbook on radiation biology.


  • Professor Kenneth Long Chair of Trustees

    Professor Ken Long is a high-energy physicist at Imperial College London and STFC, developing cutting-edge technologies to advance radiation biology and particle physics. He leads the LhARA collaboration and plays key roles in nuSTORM and MICE, major international research projects. His work bridges fundamental science and real-world medical applications.

  • Professor Pat Price

    Professor Pat Price is an internationally recognized oncologist and Visiting Professor at Imperial College London, involved in major research into cancer imaging and radiotherapy. She founded Radiotherapy UK and the Global Coalition for Radiotherapy, driving global efforts to improve access to cancer care. A passionate advocate, she leads the #CatchUpWithCancer campaign and supports cancer services in conflict zones.